On October 10, 2023 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, reported the presentation of 9 studies featuring its AI pathology research at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2023 Congress, scheduled to be held in Madrid, Spain, from October 20 to October 24, 2023 (Press release, Lunit, OCT 10, 2023, View Source [SID1234635824]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This year’s collection of abstracts delves into multifaceted research, including the use of AI-powered analysis to predict treatment outcomes in different cancer types, assess HER2 expression in breast and biliary tract cancer, and streamline clinical workflows for treatment decisions in lung cancer, all utilizing the Lunit SCOPE suite.
The highlighted abstracts for ESMO (Free ESMO Whitepaper) 2023 include:
Lunit investigates AI’s potential to predict multiple druggable mutations in non-small cell lung cancer from H&E stained images, paving the way for more efficient clinical workflows and treatment decisions.
In a collaborative study, Lunit SCOPE IO distinguishes MMR-D (Mismatch repair deficiency) from MMR-P (Mismatch repair proficiency) colon cancers by analyzing features in whole slide images, offering insights with implications for prognosis and subtype-based interventions.
Lunit evaluates the efficacy and safety of avelumab plus gemcitabine in leiomyosarcoma patients who failed first-line chemotherapy, demonstrating encouraging results in terms of response rates, duration of response, and overall survival.
Analyzing HER2 expression with Lunit SCOPE HER2 in breast cancer cases proves effective in predicting FISH (Fluorescence In Situ Hybridization) positivity and therapy response, offering valuable insights for targeted therapy.
In another study utilizing Lunit SCOPE HER2, Lunit assesses HER2 expression and TIL (Tumor-infiltrating lymphocyte) density in biliary tract cancer, providing valuable insights into the tumor microenvironment’s role in treatment strategies.
Lunit’s AI-powered spatial analysis of TIL in advanced biliary tract cancer patients, who are planning to be treated with anti-PD-1 therapy, demonstrates the potential of immune phenotypes to predict therapy outcomes.
Using Lunit SCOPE IO, a study explores the predictive role of immune phenotypes and Inflamed Score in metastatic colorectal cancer patients, providing insights into immunogenicity as a biomarker.
Lunit’s AI-powered TIL density analysis in recurrent/metastatic head and neck squamous cell carcinoma patients treated with ICI reveals favorable treatment outcomes, especially in those with higher intratumoral TIL density.
"These groundbreaking abstracts showcase the power of the Lunit SCOPE suite in unraveling complex insights across various cancer types, from distinguishing tumor subtypes to predicting treatment responses," said Brandon Suh, CEO of Lunit. "We’re on our way towards making the Lunit SCOPE suite an essential biomarker for cancer immunotherapy – contributing to the advancement of personalized oncology through innovative AI solutions."
For inquiries or to schedule a meeting with the Lunit team, please contact [email protected].